TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28727372

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 110
Study: 26678640

Group type: EXPERIMENTAL
Intervention: LAA ligation and PVI
Number of subjects: 600

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 600
Study: 23422867

Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation, 154 mg daily for 3 years
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (milk protein-matched)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation and Placebo
Number of subjects: 224
Study: 21349449

Group type: EXPERIMENTAL
Intervention: Virtual practitioner coach
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Video practitioner coach
Number of subjects: 30

Group type: COMPARATOR
Intervention: No coach
Number of subjects: 30
Study: 19371188

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional-dose statin therapy
Number of subjects: 0
Study: 16421655

Group type: EXPERIMENTAL
Intervention: Self-report Health Risk Assessment (HRA)
Number of subjects: 176

Group type: COMPARATOR
Intervention: HRA with measurement of cardiovascular (CVD) health indicators
Number of subjects: 176
Study: 14503436

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT) combined with over‐ground locomotor retraining
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional therapy program for mobility
Number of subjects: 146
Study: 10797496

Group type: EXPERIMENTAL
Intervention: Androgen blockade in addition to radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen blockade at diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate treatment for localized prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of localized disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening procedures and treatments for localized prostate cancer
Number of subjects: 0
Study: 9094060

Group type: EXPERIMENTAL
Intervention: Silent cerebral infarction
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Silent cerebral infarction (more advanced grades)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Acute cerebral infarction (within 3 days after onset)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Acute cerebral infarction (1 month after onset)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chronic cerebral infarction
Number of subjects: 88
Study: 1443705

Group type: EXPERIMENTAL
Intervention: M-K-A (midazolam 0.5 mg/kg, ketamine 3 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: M-A (midazolam 0.5 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-A (ketamine 3 mg/kg, atropine 0.02 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: A (atropine 0.02 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: M-K-A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: M-A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: M-A or M-K-A
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: K-A
Number of subjects: 100

Group type: COMPARATOR
Intervention: A
Number of subjects: 100
Study: 2947100

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 29949323

Group type: EXPERIMENTAL
Intervention: Modified natural ovulation cycle with HCG (n=32)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Mild hormonally stimulated cycle by low dose Clomiphene Citrate (n=30)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Artificial cycle induced with estradiol and progesterone supplementation (n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Comparison of endometrial thickness
Number of subjects: 123
Study: 26450116

Group type: EXPERIMENTAL
Intervention: Task Concentration Training (TCT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TCT-CT and CT-TCT sequences
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 82
Study: 24889213

Group type: EXPERIMENTAL
Intervention: Three-month outpatient rehabilitation program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual postoperative care
Number of subjects: 21
Study: 21956607

Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study: 19966584

Group type: EXPERIMENTAL
Intervention: Full-body isometric muscle resistance exergaming (EXP) during solo play
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional handheld controller (CON) during solo play
Number of subjects: 32
Study: 18405874

Group type: COMPARATOR
Intervention: Two relaxing incisions in the left eye and no incisions in the right eye
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three relaxing incisions in the left eye and no incisions in the right eye
Number of subjects: 100

Group type: COMPARATOR
Intervention: No incisions in the right eye
Number of subjects: 100
Study: 15793026

Group type: EXPERIMENTAL
Intervention: Traditional aggregate scoring method on a five-point Likert-based scale
Number of subjects: 85

Group type: COMPARATOR
Intervention: Four alternate scoring methods (including single-best-answer scoring methods)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Single-best-answer scoring with three answer choices
Number of subjects: 85
Study: 12435668

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of 400 mg ciprofloxacin over 60 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral (p.o.) dose of 500 mg ciprofloxacin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both i.v. and p.o. ciprofloxacin
Number of subjects: 8

Group type: COMPARATOR
Intervention: In vitro model simulating in vivo pharmacokinetics
Number of subjects: 8
Study: 10357120

Group type: EXPERIMENTAL
Intervention: Deflazacort oral drops
Number of subjects: 18

Group type: COMPARATOR
Intervention: Deflazacort oral tablets
Number of subjects: 18
Study: 8706449

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract
Number of subjects: 4142
Study: 1902557

Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Team nursing
Number of subjects: 0
Study: 6787746

Group type: EXPERIMENTAL
Intervention: High voltage therapy of the retrobulbar region
Number of subjects: 83
Study: 31508656

Group type: EXPERIMENTAL
Intervention: Eucalyptus grandis (8 years after transplant)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Eucalyptus grandis (6 years after transplant)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Soil Naked (control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Native Forest (control)
Number of subjects: 7
Study: 30683945

Group type: EXPERIMENTAL
Intervention: IIGI+GLP-1 (1 pmol kg-1 min-1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IIGI+GIP (4 pmol kg-1 min-1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IIGI+GIP+GLP-1 (4 and 1 pmol kg-1 min-1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: IIGI+saline (154 mmol/l NaCl; placebo)
Number of subjects: 17
Study: 28505519

Group type: EXPERIMENTAL
Intervention: Interactive situated and simulated teaching (ISST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-ISST)
Number of subjects: 31
Study: 25154888

Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Intraoperative choledochoscopy (Group B)
Number of subjects: 132
Study: 24073975

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg and 50 mg
Number of subjects: 1500
Study: 20720408

Group type: EXPERIMENTAL
Intervention: Barbecue maneuver + forced prolonged position (FPP)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Gufoni maneuver
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Barbecue maneuver + FPP
Number of subjects: 147
Study: 19169684

Group type: EXPERIMENTAL
Intervention: Fotemustine (100-75 mg/m2) administered every three weeks followed by fotemustine (100 mg/m2) every three weeks after a 5-week rest for up to 1 year.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fotemustine in patients with methylated MGMT promoter status.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fotemustine in patients with unmethylated MGMT promoter status.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Induction phase of fotemustine treatment.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Maintenance phase of fotemustine treatment.
Number of subjects: 43
Study: 16755856

Group type: EXPERIMENTAL
Intervention: Vilarinum in addition to conventional treatment (beta‐adrenoblockers, antiaggregants, and statins)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 130
Study: 15217659

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 72
Study: 12231081

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2061
Study: 9823645

Group type: EXPERIMENTAL
Intervention: Artroflow device used three times a day for 30 minutes in addition to Enoxaparin 1 x 40 mg subcutaneously per day.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group receiving only Enoxaparin 1 x 40 mg subcutaneously per day.
Number of subjects: 160
Study: 7650190

Group type: EXPERIMENTAL
Intervention: BamHI‐W PCR assay
Number of subjects: 24
Study: 2560621

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 16
Study: 785735

Group type: EXPERIMENTAL
Intervention: 30 mg/kg matrix isoniazid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of matrix isoniazid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30-40 mg/kg matrix isoniazid
Number of subjects: 0
Study: 31340793

Group type: COMPARATOR
Intervention: Low altitude (LA) rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: High altitude (HA) rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of HA vs. LA
Number of subjects: 50
Study: 27862308

Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy (10 mg intravenously once weekly for 8 weeks, escalating in 10 mg intervals)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy
Number of subjects: 13
Study: 25481662

Group type: EXPERIMENTAL
Intervention: Palliative concurrent chemoradiotherapy (CRT) with 4 courses of intravenous carboplatin and oral vinorelbine, plus radiotherapy (42 Gy in 15 fractions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 42
Study: 23774931

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol and remifentanil
Number of subjects: 160

Group type: COMPARATOR
Intervention: Manual-controlled infusion (MCI) of propofol and remifentanil
Number of subjects: 160
Study: 21627767

Group type: EXPERIMENTAL
Intervention: Micro-TENS therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 22
Study: 19366842

Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (rhCG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: follicle-stimulating hormone (FSH)
Number of subjects: 9
Study: 17122575

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rocuronium-Ketamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 15577646

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11733092

Group type: EXPERIMENTAL
Intervention: Pulsatile release tablets containing 60 mg DIL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional tablets
Number of subjects: 8
Study: 9390586

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with bupivacaine 0.125% and fentanyl 10 microg/mL
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with morphine (0.05 mg/kg bolus, 0.02 mg/kg on demand every 10 min)
Number of subjects: 124
Study: 7896423

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) intravenously (10 ng/kg/min) during surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 31
Study: 3170796

Group type: EXPERIMENTAL
Intervention: Nickel sulfate in petrolatum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nickel sulfate in aqueous solutions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nickel bioavailability from earrings and necklace
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plasma solution for leaching
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normal saline solution and synthetic sweat
Number of subjects: 12
Study: 30187612

Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on
Number of subjects: 96

Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 96
Study: 27352373

Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 47
Study: 25666517

Group type: EXPERIMENTAL
Intervention: Pain educational intervention (30 minute face-to-face meeting, leaflet, follow-up telephone call at two weeks)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study: 23438937

Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg daily)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg daily)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 326
Study: 20953794

Group type: EXPERIMENTAL
Intervention: Submaximal contractions (10-70% MVC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sustained contraction (10% MVC for 5 min)
Number of subjects: 28
Study: 18276741

Group type: EXPERIMENTAL
Intervention: Rituximab 1 g (2 infusions)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16153764

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 11 mm distance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 12 mm distance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 14 mm distance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 16 mm distance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 17 mm distance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (phosphoric acid alone)
Number of subjects: 30
Study: 15000410

Group type: EXPERIMENTAL
Intervention: Nonparametric estimation method for quantiles with correlated failure time data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation studies to investigate finite sample properties of the proposed estimators.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illustration of the proposed method with a data set from a study of patients with otitis media.
Number of subjects: 0
Study: 10826418

Group type: EXPERIMENTAL
Intervention: Laparoscopic restorative proctocolectomy
Number of subjects: 40
Study: 8865128

Group type: EXPERIMENTAL
Intervention: CDDP 40 mg/m2 + VP16 100 mg/m2 day 1‐3 (arm A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: CBDCA 250 mg/m2 day 1 + CDDP 30 mg/m2 day 2, 3 + VP16 100 mg/m2 day 1‐3 (arm B)
Number of subjects: 70
Study: 1641586

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine once daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 6567853

Group type: EXPERIMENTAL
Intervention: Four rotation postures (specific postures not detailed)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sims posture (maintenance posture)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control posture
Number of subjects: 100
Study: 30790648

Group type: EXPERIMENTAL
Intervention: Internet-first group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Phone-first group
Number of subjects: 133
Study: 29557400

Group type: EXPERIMENTAL
Intervention: 5.0 mm implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10.0 mm or longer implants
Number of subjects: 80
Study: 27371187

Group type: EXPERIMENTAL
Intervention: Attention Process Training‐II program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study: 25263780

Group type: EXPERIMENTAL
Intervention: Control enriched with 100 g/kg of extruded linseed
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Control enriched with 200 g/kg of extruded linseed
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thermised milk with starter culture
Number of subjects: 3

Group type: COMPARATOR
Intervention: Raw milk cheeses
Number of subjects: 3
Study: 23092644

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 360
Study: 20145166

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 day 1 every 3 weeks)
Number of subjects: 161
Study: 18042476

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (mecobalamin 500 mg + multivitamin supplement containing B6 5 mg, folic acid 1 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 89
Study: 11240506

Group type: EXPERIMENTAL
Intervention: Hysterography
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Transvaginal sonohysterography
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 38
Study: 9429363

Group type: EXPERIMENTAL
Intervention: Polyvinyl chloride (PVC) device
Number of subjects: 71

Group type: COMPARATOR
Intervention: Disposable nursing pad
Number of subjects: 71
Study: 8389269

Group type: EXPERIMENTAL
Intervention: Ulinastatin (100 U/mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 12
Study: 3548612

Group type: EXPERIMENTAL
Intervention: 50% branched chain enriched formula (MAA) (Travasol + Branchamin concentrate) at a dose of 1.0-2.0 g/kg/day
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard amino acid formula (SAA) (Travasol) at a dose of 1.0-2.0 g/kg/day
Number of subjects: 87
Study: 31715580

Group type: EXPERIMENTAL
Intervention: Positively framed self-efficacy questionnaire
Number of subjects: 275

Group type: COMPARATOR
Intervention: Negatively framed self-efficacy questionnaire
Number of subjects: 275
Study: 30025526

Group type: EXPERIMENTAL
Intervention: Reconstruction with bone cement and cancellous screws (R group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No reconstruction (NR group)
Number of subjects: 20
Study: 28778151

Group type: EXPERIMENTAL
Intervention: Algorithm of muscle function tests (four tests: arm lift, head lift, swallowing or eye opening)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Uncalibrated acceleromyography
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tactile judgement of TOF fading
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Algorithm of muscle function tests
Number of subjects: 165
Study: 24382021

Group type: EXPERIMENTAL
Intervention: Short Intervals (SI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Long Intervals (LI)
Number of subjects: 16
Study: 24246427

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Education control arm (n=24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Text messaging adherence
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Text messaging adherence and weight loss correlation
Number of subjects: 50
Study: 21051593

Group type: EXPERIMENTAL
Intervention: Treadmill-based training with manual assistance (TM)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Treadmill-based training with stimulation (TS)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Overground training with stimulation (OG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Treadmill-based training with robotic assistance (LR)
Number of subjects: 74
Study: 18323476

Group type: COMPARATOR
Intervention: AR genetic variation (haplotype-tagging single nucleotide polymorphisms and CAG repeat number)
Number of subjects: 300

Group type: COMPARATOR
Intervention: CAG repeat length >or=21 or >or=22
Number of subjects: 300
Study: 17147104

Group type: EXPERIMENTAL
Intervention: Regression equations based on age, gender, and estimated premorbid IQ as predictors
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Age and premorbid IQ
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 272
Study: 12698766

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 11063440

Group type: EXPERIMENTAL
Intervention: Pork diet (29% of energy as fat and 29% as protein, mainly from pork meat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soy diet (29% of energy as fat and 28% as protein, mainly from soy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate diet (28% of energy as fat and 11% as protein)
Number of subjects: 12
Study: 8814468

Group type: EXPERIMENTAL
Intervention: DEEF
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEEP
Number of subjects: 20

Group type: COMPARATOR
Intervention: IPPV
Number of subjects: 20